Using a <i>Caenorhabditis elegans</i> Parkinson’s Disease Model to Assess Disease Progression and Therapy Efficiency

Using a <i>Caenorhabditis elegans</i> Parkinson’s Disease Model to Assess Disease Progression and Therapy Efficiency

Despite Parkinson’s Disease (PD) being the second most common neurodegenerative disease, treatment options are limited. Consequently, there is an urgent need to identify and screen new therapeutic compounds that slow or reverse the pathology of PD. Unfortunately, few new therapeutics are being produ...

Full description

Bibliographic Details
Main Authors: Samantha Hughes, Maritza van Dop, Nikki Kolsters, David van de Klashorst, Anastasia Pogosova, Anouk M. Rijs
Format: Article
Language:English
Published: MDPI AG 2022-04-01
Series:Pharmaceuticals
Subjects:
<i>C. elegans</i>
α-synuclein aggregation
lifespan
mobility
screening platform
therapeutics
Online Access:https://www.mdpi.com/1424-8247/15/5/512

Internet

https://www.mdpi.com/1424-8247/15/5/512

Similar Items